{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:56:47Z","timestamp":1792277807583,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["U01MH092250"],"award-info":[{"award-number":["U01MH092250"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["U01MH092250"],"award-info":[{"award-number":["U01MH092250"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["U01MH092221"],"award-info":[{"award-number":["U01MH092221"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["U01MH092250"],"award-info":[{"award-number":["U01MH092250"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41386-018-0122-9","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T01:13:20Z","timestamp":1529370800000},"page":"2221-2230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder"],"prefix":"10.1038","volume":"43","author":[{"given":"Elizabeth A.","family":"Bartlett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"DeLorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Petkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrna","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Todd","family":"Ogden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benji T.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Malchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal M.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Trombello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"McInnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Oquendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Pizzagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-1110","authenticated-orcid":false,"given":"Madhukar","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin V.","family":"Parsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"key":"122_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340.","journal-title":"Am J Psychiatry"},{"key":"122_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/archpsyc.1987.01800150071009","volume":"44","author":"FM Quitkin","year":"1987","unstructured":"Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry. 1987;44:259\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"122_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/archpsyc.59.10.877","volume":"59","author":"HC Kraemer","year":"2002","unstructured":"Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59:877\u201383.","journal-title":"Arch Gen Psychiatry"},{"key":"122_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jamapsychiatry.2013.143","volume":"70","author":"CL McGrath","year":"2013","unstructured":"McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013;70:821\u20139.","journal-title":"JAMA Psychiatry"},{"key":"122_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jad.2011.04.010","volume":"133","author":"SJ Colloby","year":"2011","unstructured":"Colloby SJ, Firbank MJ, Vasudev A, Parry SW, Thomas AJ, O\u2019Brien JT. Cortical thickness and VBM-DARTEL in late-life depression. J Affect Disord. 2011;133:158\u201364.","journal-title":"J Affect Disord"},{"key":"122_CR6","first-page":"423","volume":"33","author":"T Frodl","year":"2008","unstructured":"Frodl T, Jager M, Smajstrlova I, Born C, Bottlender R, Palladino T, et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci. 2008;33:423\u201330.","journal-title":"J Psychiatry Neurosci"},{"key":"122_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1600-0447.2011.01766.x","volume":"124","author":"H Jarnum","year":"2011","unstructured":"Jarnum H, Eskildsen SF, Steffensen EG, Lundbye-Christensen S, Simonsen CW, Thomsen IS, et al. Longitudinal MRI study of cortical thickness, perfusion, and metabolite levels in major depressive disorder. Acta Psychiatr Scand. 2011;124:435\u201346.","journal-title":"Acta Psychiatr Scand"},{"key":"122_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.euroneuro.2010.02.010","volume":"20","author":"PC Koolschijn","year":"2010","unstructured":"Koolschijn PC, van Haren NE, Schnack HG, Janssen J, Hulshoff Pol HE, Kahn RS. Cortical thickness and voxel-based morphometry in depressed elderly. Eur Neuropsychopharmacol. 2010;20:398\u2013404.","journal-title":"Eur Neuropsychopharmacol"},{"key":"122_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neuroscience.2013.12.058","volume":"262","author":"CH Liu","year":"2014","unstructured":"Liu CH, Jing B, Ma X, Xu PF, Zhang Y, Li F, et al. Voxel-based morphometry study of the insular cortex in female patients with current and remitted depression. Neuroscience. 2014;262:190\u20139.","journal-title":"Neuroscience"},{"key":"122_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1503\/jpn.100002","volume":"35","author":"NV Malykhin","year":"2010","unstructured":"Malykhin NV, Carter R, Seres P, Coupland NJ. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci. 2010;35:337\u201343.","journal-title":"J Psychiatry Neurosci"},{"key":"122_CR11","first-page":"41","volume":"34","author":"MC McKinnon","year":"2009","unstructured":"McKinnon MC, Yucel K, Nazarov A, MacQueen GM. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci. 2009;34:41\u201354.","journal-title":"J Psychiatry Neurosci"},{"key":"122_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/mp.2016.60","volume":"22","author":"L Schmaal","year":"2016","unstructured":"Schmaal L,Hibar DP,Samann PG,Hall GB,Baune BT,Jahanshad N, et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Mol Psychiatry. 2016a;22:900\u20139.","journal-title":"Mol Psychiatry"},{"key":"122_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/mp.2015.69","volume":"21","author":"L Schmaal","year":"2016","unstructured":"Schmaal L,Veltman DJ,van Erp TG,Samann PG,Frodl T,Jahanshad N, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry. 2016b;21:806\u201312.","journal-title":"Mol Psychiatry"},{"key":"122_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jad.2009.06.003","volume":"121","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, Yucel M, Lorenzetti V, Tanino R, Whittle S, Suzuki M, et al. Volumetric MRI study of the insular cortex in individuals with current and past major depression. J Affect Disord. 2010;121:231\u20138.","journal-title":"J Affect Disord"},{"key":"122_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.pscychresns.2013.09.003","volume":"214","author":"W Truong","year":"2013","unstructured":"Truong W, Minuzzi L, Soares CN, Frey BN, Evans AC, MacQueen GM, et al. Changes in cortical thickness across the lifespan in major depressive disorder. Psychiatry Res. 2013;214:204\u201311.","journal-title":"Psychiatry Res"},{"key":"122_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.pscychresns.2011.07.011","volume":"202","author":"PC Tu","year":"2012","unstructured":"Tu PC, Chen LF, Hsieh JC, Bai YM, Li CT, Su TP. Regional cortical thinning in patients with major depressive disorder: a surface-based morphometry study. Psychiatry Res. 2012;202:206\u201313.","journal-title":"Psychiatry Res"},{"key":"122_CR17","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1176\/appi.ajp.2013.12121504","volume":"170","author":"P van Eijndhoven","year":"2013","unstructured":"van Eijndhoven P, van Wingen G, Katzenbauer M, Groen W, Tepest R, Fernandez G, et al. Paralimbic cortical thickness in first-episode depression: evidence for trait-related differences in mood regulation. Am J Psychiatry. 2013;170:1477\u201386.","journal-title":"Am J Psychiatry"},{"key":"122_CR18","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jpsychires.2012.07.013","volume":"46","author":"G Wagner","year":"2012","unstructured":"Wagner G, Schultz CC, Koch K, Schachtzabel C, Sauer H, Schlosser RG. Prefrontal cortical thickness in depressed patients with high-risk for suicidal behavior. J Psychiatr Res. 2012;46:1449\u201355.","journal-title":"J Psychiatr Res"},{"key":"122_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1176\/ajp.157.1.115","volume":"157","author":"JD Bremner","year":"2000","unstructured":"Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157:115\u20138.","journal-title":"Am J Psychiatry"},{"key":"122_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/cercor\/12.4.386","volume":"12","author":"D Cotter","year":"2002","unstructured":"Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex. 2002;12:386\u201394.","journal-title":"Cereb Cortex"},{"key":"122_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archpsyc.58.6.545","volume":"58","author":"D Cotter","year":"2001","unstructured":"Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58:545\u201353.","journal-title":"Arch Gen Psychiatry"},{"key":"122_CR22","doi-asserted-by":"publisher","first-page":"13290","DOI":"10.1073\/pnas.95.22.13290","volume":"95","author":"D Ongur","year":"1998","unstructured":"Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA. 1998;95:13290\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"122_CR23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0006-3223(99)00041-4","volume":"45","author":"G Rajkowska","year":"1999","unstructured":"Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085\u201398.","journal-title":"Biol Psychiatry"},{"key":"122_CR24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1001\/archpsyc.57.10.925","volume":"57","author":"RM Sapolsky","year":"2000","unstructured":"Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925\u201335.","journal-title":"Arch Gen Psychiatry"},{"key":"122_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.biopsych.2014.10.018","volume":"78","author":"M Papmeyer","year":"2015","unstructured":"Papmeyer M, Giles S, Sussmann JE, Kielty S, Stewart T, Lawrie SM, et al. Cortical thickness in individuals at high familial risk of mood disorders as they develop major depressive disorder. Biol Psychiatry. 2015;78:58\u201366.","journal-title":"Biol Psychiatry"},{"key":"122_CR26","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1073\/pnas.0805311106","volume":"106","author":"BS Peterson","year":"2009","unstructured":"Peterson BS, Warner V, Bansal R, Zhu H, Hao X, Liu J, et al. Cortical thinning in persons at increased familial risk for major depression. Proc Natl Acad Sci USA. 2009;106:6273\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"122_CR27","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1176\/appi.ajp.161.11.1957","volume":"161","author":"P Videbech","year":"2004","unstructured":"Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957\u201366.","journal-title":"Am J Psychiatry"},{"key":"122_CR28","doi-asserted-by":"publisher","first-page":"e6353","DOI":"10.1371\/journal.pone.0006353","volume":"4","author":"SG Costafreda","year":"2009","unstructured":"Costafreda SG, Chu C, Ashburner J, Fu CH. Prognostic and diagnostic potential of the structural neuroanatomy of depression. PLoS One. 2009;4:e6353.","journal-title":"PLoS One"},{"key":"122_CR29","unstructured":"Fonseka TM, MacQueen GM, Kennedy SH. Neuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder. J Affect Disord. 2017;223:21\u201335."},{"key":"122_CR30","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.biopsych.2008.06.027","volume":"64","author":"GM MacQueen","year":"2008","unstructured":"MacQueen GM, Yucel K, Taylor VH, Macdonald K, Joffe R. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol Psychiatry. 2008;64:880\u20133.","journal-title":"Biol Psychiatry"},{"key":"122_CR31","doi-asserted-by":"crossref","unstructured":"Phillips JL, Batten LA, Tremblay P, Aldosary F, Blier P. A prospective, longitudinal study of the effect of remission on cortical thickness and hippocampal volume in patients with treatment-resistant depression. international J Neuropsychopharmacol. 2015;18:pyv037.","DOI":"10.1093\/ijnp\/pyv037"},{"key":"122_CR32","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0006-3223(99)00296-6","volume":"47","author":"K Vakili","year":"2000","unstructured":"Vakili K, Pillay SS, Lafer B, Fava M, Renshaw PF, Bonello-Cintron CM, et al. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol Psychiatry. 2000;47:1087\u201390.","journal-title":"Biol Psychiatry"},{"key":"122_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.biopsych.2006.09.018","volume":"62","author":"CH Chen","year":"2007","unstructured":"Chen CH, Ridler K, Suckling J, Williams S, Fu CH, Merlo-Pich E, et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry. 2007;62:407\u201314.","journal-title":"Biol Psychiatry"},{"key":"122_CR34","unstructured":"Bansal R, Hellerstein DJ, Peterson BS. Evidence for neuroplastic compensation in the cerebral cortex of persons with depressive illness. Mol Psychiatry. 2017;34:375\u201383."},{"key":"122_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jpsychires.2016.03.001","volume":"78","author":"MH Trivedi","year":"2016","unstructured":"Trivedi MH, McGrath PJ, Fava M, Parsey RV, Kurian BT, Phillips ML, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design. J Psychiatr Res. 2016;78:11\u201323.","journal-title":"J Psychiatr Res"},{"key":"122_CR36","first-page":"78","volume-title":"DSM-IV-TR: Diagnostic and statistical manual of mental disorders, text revision.","author":"AP Association","year":"2000","unstructured":"Association AP, Association AP. DSM-IV-TR: Diagnostic and statistical manual of mental disorders, text revision. 75. Washington, DC: American Psychiatric Association; 2000. p. 78\u201385."},{"key":"122_CR37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573\u201383.","journal-title":"Biol Psychiatry"},{"key":"122_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"122_CR39","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1002\/hbm.22856","volume":"36","author":"Z Iscan","year":"2015","unstructured":"Iscan Z, Jin TB, Kendrick A, Szeglin B, Lu H, Trivedi M, et al. Test\u2013retest reliability of freesurfer measurements within and between sites: effects of visual approval process. Hum Brain Mapp. 2015;36:3472\u201385.","journal-title":"Hum Brain Mapp"},{"key":"122_CR40","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968\u201380.","journal-title":"Neuroimage"},{"key":"122_CR41","doi-asserted-by":"crossref","unstructured":"Fortin J-P, Cullen N, Sheline YI, Taylor WD, Aselcioglu I, Adams P, et al. Harmonization of cortical thickness measurements across scanners and sites. Neuroimage. 2018;167:104\u2013120.","DOI":"10.1016\/j.neuroimage.2017.11.024"},{"key":"122_CR42","doi-asserted-by":"publisher","first-page":"e2669","DOI":"10.1371\/journal.pone.0002669","volume":"3","author":"J Driemeyer","year":"2008","unstructured":"Driemeyer J, Boyke J, Gaser C, B\u00fcchel C, May A. Changes in gray matter induced by learning\u2014revisited. PLoS One. 2008;3:e2669.","journal-title":"PLoS One"},{"key":"122_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.102","volume":"6","author":"T Pirnia","year":"2016","unstructured":"Pirnia T, Joshi S, Leaver A, Vasavada M, Njau S, Woods R, et al. Electroconvulsive therapy and structural neuroplasticity in neocortical, limbic and paralimbic cortex. Transl Psychiatry. 2016;6:e832.","journal-title":"Transl Psychiatry"},{"issue":"Suppl 4","key":"122_CR44","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1016\/S0924-977X(03)91899-2","volume":"13","author":"CC Nemeroff","year":"2003","unstructured":"Nemeroff CC,Entsuah AR,Willard L,Demitrack M,Thase M, Venlafaxine and SSRIs: pooled remission analysis. Eur Neuropsychopharmacol. 2003;13(Suppl 4):S255","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Pt 1","key":"122_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/brain\/118.1.279","volume":"118","author":"O Devinsky","year":"1995","unstructured":"Devinsky O,Morrell MJ,Vogt BA, Contributions of anterior cingulate cortex to behaviour. Brain. 1995;118(Pt 1):279\u2013306.","journal-title":"Brain"},{"key":"122_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/npp.2010.166","volume":"36","author":"DA Pizzagalli","year":"2011","unstructured":"Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacol. 2011;36:183\u2013206.","journal-title":"Neuropsychopharmacol"},{"key":"122_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1192\/bjp.bp.108.051193","volume":"195","author":"CJ Harmer","year":"2009","unstructured":"Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009a;195:102\u20138.","journal-title":"Br J Psychiatry"},{"key":"122_CR48","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1176\/appi.ajp.2009.09020149","volume":"166","author":"CJ Harmer","year":"2009","unstructured":"Harmer CJ,O\u2019Sullivan U,Favaron E,Massey-Chase R,Ayres R,Reinecke A, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009b;166:1178\u201384.","journal-title":"Am J Psychiatry"},{"key":"122_CR49","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1176\/appi.ajp.161.7.1256","volume":"161","author":"CJ Harmer","year":"2004","unstructured":"Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004;161:1256\u201363.","journal-title":"Am J Psychiatry"},{"key":"122_CR50","doi-asserted-by":"crossref","unstructured":"Brennan BP, Admon R, Perriello C, LaFlamme EM, Athey AJ, Pizzagalli DA, et al. Acute change in anterior cingulate cortex GABA, but not glutamine\/glutamate, mediates antidepressant response to citalopram. Psychiatry Res: Neuroimaging. 2017;269:9\u201316.","DOI":"10.1016\/j.pscychresns.2017.08.009"},{"key":"122_CR51","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/0165-6147(94)90315-8","volume":"15","author":"P Blier","year":"1994","unstructured":"Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 1994;15:220\u20136.","journal-title":"Trends Pharmacol Sci"},{"key":"122_CR52","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0166-2236(96)10037-0","volume":"19","author":"F Artigas","year":"1996","unstructured":"Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996;19:378\u201383.","journal-title":"Trends Neurosci"},{"key":"122_CR53","unstructured":"Norman TR. The new antidepressants-mechanisms of action. Issues. 1999;22:106\u20138."},{"key":"122_CR54","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1749-6632.1998.tb10192.x","volume":"861","author":"P Blier","year":"1998","unstructured":"Blier P, Pineyro G, el Mansari M, Bergeron R, de Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann N Y Acad Sci. 1998;861:204\u201316.","journal-title":"Ann N Y Acad Sci"},{"key":"122_CR55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/archpsyc.1994.03950030084009","volume":"51","author":"F Artigas","year":"1994","unstructured":"Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994;51:248\u201351.","journal-title":"Arch Gen Psychiatry"},{"key":"122_CR56","doi-asserted-by":"crossref","unstructured":"Pillai RL, Malhotra A, Rupert DD, Weschler B, Williams JC, Zhang M, et al. Relations between cortical thickness, serotonin 1A receptor binding, and structural connectivity: a multimodal imaging study. Hum Brain Mapp. 2018;39:1043\u201355.","DOI":"10.1002\/hbm.23903"},{"key":"122_CR57","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1176\/appi.ajp.159.5.728","volume":"159","author":"HS Mayberg","year":"2002","unstructured":"Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159:728\u201337.","journal-title":"Am J Psychiatry"},{"key":"122_CR58","first-page":"68","volume":"1","author":"M Sikora","year":"2016","unstructured":"Sikora M, Heffernan J, Avery ET, Mickey BJ, Zubieta J-K, Peci\u00f1a M. Salience network functional connectivity predicts placebo effects in major depression. Biol Psychiatry. 2016;1:68\u201376.","journal-title":"Biol Psychiatry"},{"key":"122_CR59","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1176\/appi.ajp.159.1.122","volume":"159","author":"AF Leuchter","year":"2002","unstructured":"Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002;159:122\u20139.","journal-title":"Am J Psychiatry"},{"key":"122_CR60","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S0140-6736(78)92762-9","volume":"2","author":"JD Levine","year":"1978","unstructured":"Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet. 1978;2:654\u20137.","journal-title":"Lancet"},{"key":"122_CR61","doi-asserted-by":"crossref","unstructured":"Pecina M, Bohnert A, Sikora M, Avery E, Langenecker S, Mickey B, et al. Placebo-activated neural systems are linked to antidepressant responses. JAMA Psychiatry. 2015;72:1087\u201394.","DOI":"10.1001\/jamapsychiatry.2015.1335"},{"key":"122_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pain.2010.03.011","volume":"150","author":"P Petrovic","year":"2010","unstructured":"Petrovic P, Kalso E, Petersson KM, Andersson J, Fransson P, Ingvar M. A prefrontal non-opioid mechanism in placebo analgesia. Pain. 2010;150:59\u201365.","journal-title":"Pain"},{"key":"122_CR63","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1192\/bjp.bp.113.140343","volume":"205","author":"AF Leuchter","year":"2014","unstructured":"Leuchter AF, Hunter AM, Tartter M, Cook IA. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry. 2014;205:443\u20139.","journal-title":"Br J Psychiatry"},{"key":"122_CR64","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/archpsyc.1989.01810120022005","volume":"46","author":"JW Stewart","year":"1989","unstructured":"Stewart JW, Quitkin M. Chronicity of antidepressant efficacy in atypical depression. Arch Gen Psychiatry. 1989;46:1080\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"122_CR65","doi-asserted-by":"publisher","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","volume":"133","author":"R Temple","year":"2000","unstructured":"Temple R,Ellenberg SS, Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455\u201363.","journal-title":"Ann Intern Med"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0122-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0122-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0122-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:29Z","timestamp":1684616609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0122-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["122"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0122-9","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"16 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<b>Ms. Bartlett, Dr. Ogden<\/b>, <b>Ms. Malchow<\/b>, and <b>Dr. Petkova<\/b> report no conflicting interests. <b>Dr. Yang, Dr. Sharma<\/b>, and <b>Ms. Zhang<\/b> report no conflicting interests relating to this paper. <b>Dr. DeLorenzo<\/b> reports no financial disclosures. <b>Dr. Cooper<\/b> and <b>Dr. Adams<\/b> report no competing interests. <b>Dr. McInnis<\/b> has no conflicts of interest with respect to this paper. <b>Dr. Trombello<\/b> owns stock in Merck and Gilead Sciences. Within the past 36 months he has also owned stock in Johnson & Johnson. <b>Dr. Trivedi<\/b>, is or has been an advisor\/consultant and received fee from (lifetime disclosure): Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Fabre Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical\/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories. In addition, he has received grants\/research support from: Agency for Healthcare Research and Quality (AHRQ), Cyberonics, Inc., National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health and National Institute on Drug Abuse. In the past two years, <b>Dr. Weissman<\/b> received funding from the National Institute of Mental Health (NIMH), the National Alliance for Research on Schizophrenia and Depression (NARSAD), the Sackler Foundation, the Templeton Foundation; and receives royalties from the Oxford University Press, Perseus Press, the American Psychiatric Association Press, and MultiHealth Systems. <b>Dr. McGrath<\/b> has received funding from the National Institute of Mental Health, New York State Department of Mental Hygiene, Research Foundation for Mental Hygiene (New York State), Forest Research Laboratories, Sunovion Pharmaceuticals, and Naurex Pharmaceuticals (now Allergan). <b>Dr. Fava<\/b> has received research support from Abbot Laboratories; Alkermes, Inc.; American Cyanamid; Aspect Medical Systems; AstraZeneca; Avanir Pharmaceuticals; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Clintara, LLC; Cerecor; Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus\/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante; Methylation Sciences Inc.; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.; Pharmavite\u00ae LLC; PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Tal Medical; Wyeth-Ayerst Laboratories; he has served as advisor or consultant to Abbott Laboratories; Acadia; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AG; Best Practice Project Management, Inc.; Biogen; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Forum Pharmaceuticals; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus\/Ingenis; Intracellular; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Nestle Health Sciences; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Osmotica; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite\u00ae LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; RCT Logic, LLC Formerly Clinical Trials Solutions, LLC; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Taisho Pharmaceutical; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.; VistaGen; he has received speaking or publishing fees from Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute\/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy\/Primedia; MGH Psychiatry Academy\/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource, Corp.; Wyeth-Ayerst Laboratories; he has equity holdings in Compellis and PsyBrain, Inc.; he has a patent for Sequential Parallel Comparison Design (SPCD), which are licensed by MGH to Pharmaceutical Product Development, LLC (PPD); and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven; and he receives copyright royalties for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), Symptoms of Depression Questionnaire (SDQ), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte.Ltd. <b>Dr. Kurian<\/b> has received research grant support from the following organizations: Targacept, Inc., Pfizer, Inc., Johnson & Johnson, Evotec, Rexahn, Naurex, Forest Pharmaceuticals and the National Institute of Mental Health (NIMH). Mary L. Phillips has received funding from NIMH and the Emmerling-Pittsburgh Foundation. <b>Dr. Oquendo<\/b> receives royalties for use of the Columbia Suicide Severity Rating Scale. Her family owns stock in Bristol Myers Squibb. Over the past 3 years, <b>Dr. Pizzagalli<\/b> has received honoraria\/consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Pfizer, and Posit Science for activities unrelated to this project. <b>Dr. Parsey<\/b> reports no relevant or material financial interests that relate to the research described in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}